ABT 📈 Abbott Laboratories - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0028241000

ABT: Pharmaceuticals, Diagnostic Tools, Nutritionals, Medical Devices

Abbott Laboratories is a multinational healthcare company that develops, manufactures, and markets a wide range of healthcare products globally. The company operates through four primary segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its pharmaceutical offerings include a diverse portfolio of generic medications for treating various conditions, such as pancreatic exocrine insufficiency, irritable bowel syndrome, and hormone replacement therapy, as well as anti-infective medications like clarithromycin and influenza vaccines. Additionally, Abbott provides products that regulate the physiological rhythm of the colon, addressing gastrointestinal health.

The company's diagnostic product portfolio is equally extensive, featuring laboratory and transfusion medicine systems that cater to immunoassay, clinical chemistry, hematology, and transfusion needs. It also offers molecular diagnostics solutions, including polymerase chain reaction instrument systems that automate DNA and RNA extraction, purification, and preparation from patient samples, enabling the detection and measurement of infectious agents. Point-of-care systems, cartridges for testing various blood parameters, rapid diagnostics lateral flow testing products, and molecular point-of-care testing solutions for diseases like HIV, SARS-CoV-2, and influenza are also part of its offerings. Furthermore, Abbott provides cardiometabolic test systems, drug and alcohol testing solutions, remote patient monitoring systems, and consumer self-test systems, along with informatics and automation solutions for laboratories to enhance efficiency and accuracy.

Abbott's nutritional products cater to both pediatric and adult needs, providing essential nutrients for growth and maintenance of health. The company is also a significant player in the medical devices sector, particularly in the treatment of cardiovascular diseases, offering rhythm management, electrophysiology, heart failure, vascular, and structural heart devices. Its diabetes care products include glucose and blood glucose monitoring systems, which are crucial for managing diabetes. Additionally, Abbott develops and markets neuromodulation devices designed to manage chronic pain and movement disorders, improving the quality of life for patients with these conditions.

With a rich history dating back to 1888, Abbott Laboratories is headquartered in North Chicago, Illinois. The company's commitment to innovation and its broad spectrum of healthcare products and services position it as a leader in the global healthcare industry. Its presence is felt worldwide, with a significant online presence at https://www.abbott.com, and it is listed on the New York Stock Exchange (NYSE) under the ticker symbol ABT, with the ISIN US0028241000, classified as a common stock under the GICS Sub Industry: Health Care Equipment.

Additional Sources for ABT Stock

ABT Stock Overview

Market Cap in USD 197,971m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Health Care Equipment
IPO / Inception 1978-01-13

ABT Stock Ratings

Growth 5y 30.7%
Fundamental 50.5%
Dividend 64.7%
Rel. Strength Industry 313
Analysts 4.22/5
Fair Price Momentum 106.90 USD
Fair Price DCF 96.75 USD

ABT Dividends

Dividend Yield 12m 1.95%
Yield on Cost 5y 2.78%
Annual Growth 5y 8.85%
Payout Consistency 96.7%

ABT Growth Ratios

Growth Correlation 3m -39.9%
Growth Correlation 12m 35%
Growth Correlation 5y 31.1%
CAGR 5y 7.36%
CAGR/Mean DD 5y 0.51
Sharpe Ratio 12m -0.02
Alpha -19.07
Beta 0.76
Volatility 17.84%
Current Volume 6037.2k
Average Volume 20d 4849.1k
What is the price of ABT stocks?
As of January 07, 2025, the stock is trading at USD 113.04 with a total of 6,037,209 shares traded.
Over the past week, the price has changed by +0.21%, over one month by -2.21%, over three months by +0.19% and over the past year by +2.58%.
Is Abbott Laboratories a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Abbott Laboratories (NYSE:ABT) is currently (January 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 50.50 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ABT as of January 2025 is 106.90. This means that ABT is currently overvalued and has a potential downside of -5.43%.
Is ABT a buy, sell or hold?
Abbott Laboratories has received a consensus analysts rating of 4.22. Therefor, it is recommend to buy ABT.
  • Strong Buy: 13
  • Buy: 8
  • Hold: 5
  • Sell: 1
  • Strong Sell: 0
What are the forecast for ABT stock price target?
According to ValueRays Forecast Model, ABT Abbott Laboratories will be worth about 117.5 in January 2026. The stock is currently trading at 113.04. This means that the stock has a potential upside of +3.95%.
Issuer Forecast Upside
Wallstreet Target Price 129.9 14.9%
Analysts Target Price 110.7 -2.1%
ValueRay Target Price 117.5 4%